News FDA approves Lilly’s once-weekly basal insulin Onswik for type 2 diabetes pharminent September 24, 2026
News FDA approves Ultragenyx’s gene therapy Fayuvi for Sanfilippo syndrome type A pharminent September 18, 2026
News NICE Clears Enhertu in HER2-Low Breast Cancer After England Raised Its Cost-Effectiveness Threshold pharminent September 17, 2026
News Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer’s pharminent September 16, 2026
News GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma pharminent September 15, 2026
News Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning pharminent September 14, 2026
News FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent pharminent September 11, 2026
News Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer pharminent September 10, 2026
News FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation pharminent September 9, 2026
News Novartis’s Del-Desiran Misses Primary Endpoint in HARBOR, Putting the $12B Avidity Deal Under Scrutiny pharminent September 8, 2026
News Novartis and Ionis’ Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes pharminent September 7, 2026
News Ionis Wins First-Ever FDA Approval for Alexander Disease with Zanvastro pharminent September 4, 2026
News Ivonescimab Beats Keytruda on Survival in China-Only Trial as Its Global Study Stumbles pharminent September 3, 2026
News UK Suspends Amgen’s Tavneos for New Patients as a Data-Integrity Cascade Spreads Across Three Regulators pharminent September 2, 2026
News Novartis Posts Phase 3 MS Win and Halts Eight Autoimmune CAR-T Trials pharminent September 1, 2026
News Lilly Pays Up to $2.875 Billion for Merida and a Phase 1 Autoantibody Platform pharminent August 31, 2026
News FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 Diabetes pharminent August 28, 2026
News FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis pharminent August 28, 2026
News FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer pharminent August 26, 2026
News FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease pharminent August 25, 2026
News Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 Billion pharminent August 24, 2026
News Johnson & Johnson Wins EU Approval for Tecvayli-Daratumumab in Second-Line Myeloma pharminent August 21, 2026
News Regeneron’s Pasatru Wins Full FDA Approval for Ultra-Rare ‘Stone Man Disease’ pharminent August 20, 2026
News Moderna and Merck’s Personalized Melanoma Vaccine Scores Historic Phase 3 Win pharminent August 19, 2026
News Amylyx’s Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric Hypoglycemia pharminent August 18, 2026
News AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline pharminent August 17, 2026
News BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma pharminent August 14, 2026
News Eli Lilly Files Six Lawsuits to Combat Illegal Retatrutide Black Market pharminent August 12, 2026
News Trump Executive Order Strips Seven Vaccines From Childhood Immunization Recommendations pharminent August 11, 2026
News FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu Vaccine pharminent August 6, 2026
News Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 Surge pharminent August 5, 2026
News Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout pharminent August 4, 2026
News AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks pharminent August 3, 2026